Zacks: Allogene Therapeutics Inc (ALLO) Given $30.00 Average Target Price by Analysts

Shares of Allogene Therapeutics Inc (NASDAQ:ALLO) have been assigned a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and two have assigned a strong buy recommendation to the company.

Analysts have set a 1 year consensus target price of $30.00 for the company and are anticipating that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also assigned Allogene Therapeutics an industry rank of 70 out of 257 based on the ratings given to related companies.

ALLO has been the topic of a number of analyst reports. Jefferies Financial Group initiated coverage on shares of Allogene Therapeutics in a research note on Monday, November 5th. They issued a “buy” rating and a $31.00 price target on the stock. Cowen initiated coverage on shares of Allogene Therapeutics in a research note on Monday, November 5th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. initiated coverage on shares of Allogene Therapeutics in a research note on Monday, November 5th. They issued a “neutral” rating and a $29.00 price target on the stock. Finally, Goldman Sachs Group initiated coverage on shares of Allogene Therapeutics in a research note on Monday, November 5th. They issued a “buy” rating and a $41.00 price target on the stock.

Allogene Therapeutics stock traded down $3.39 during mid-day trading on Thursday, reaching $27.06. The stock had a trading volume of 1,439,500 shares, compared to its average volume of 710,403. Allogene Therapeutics has a one year low of $21.67 and a one year high of $35.55.

In related news, Director Arie Belldegrun bought 35,000 shares of the stock in a transaction on Monday, October 15th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $630,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider David D. Chang bought 40,000 shares of the stock in a transaction on Monday, October 15th. The shares were bought at an average price of $18.00 per share, for a total transaction of $720,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 750,000 shares of company stock worth $13,500,000.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent.

Read More: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Allogene Therapeutics (ALLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply